Tuesday, August 3, 2010 – Before Market Open

Introductory Coverage

New “Trading Alert”

 

 

A5 Laboratories, Inc.

(OTCBB: AFLB - $.88 per share)

www.A5Labs.com  

Tim Fields of Untapped Wealth Issues Investor Action Bulletin on AFLB stating they have, “Just Announced the Greatest Medical Discovery of the 21^st Century” and to “Watch your $5,000 blossom into $249,726” 

“A5 Laboratories can make natural Interferon 100 times cheaper than any competitor … And their product is 100 to 1,000 times more potent …

Two weeks ago, The Green Baron Report introduced Gold American Mining Corp. (BB: SILA) at .65 per share as its first new “Trading Alert” in over three months.  In just six trading days, SILA rallied to hit a short-term high of $1.16 per share up over 78%.

Today, The Green Baron Report introduces our new “Trading Alert” A5 Laboratories, Inc. (BB: AFLB).  Last week, A5 Labs announced it submitted a provisional patent application to protect its technology for the production of interferon-based products.  Its lead product has potential broad based applications for the treatment of certain types of cancer as well as multiple sclerosis and viral infections.  We believe this is a significantly positive development and that research coverage of AFLB will continue to expand.  We predict that investors will aggressively accumulate this stock particularly over the near-term.

Tim Fields of Untapped Wealth is one stock newsletter editor that is wildly bullish over the prospects of A5 Laboratories and its stock AFLB.  He goes on to say, “I’ll prove … why a buyout by Pfizer, Merck or Johnson & Johnson may be virtually guaranteed!”  See a portion of this report below, and click the link at the bottom to view it in its entirety.  This appears to be a great trading opportunity.

Independent Third Party “BUY” Recommendation and Alert

 

Dear Fellow Investor:

How often do you have the opportunity to buy shares of a company that will “completely take over a $9 billion industry,” rendering all competitive products obsolete overnight?

How often can you buy shares (for $1) before Wall Street and the investing herd has a clue as to the transformative nature of the company’s breakthrough?

How often can you watch your company, not just dominate its market, but expand it to $12, $18, even $27 billion because they can cut prices 7-fold, even while maintaining profit margins in excess of 93%!

That’s the opportunity we have with A5 Laboratories: symbol AFLB on the OTCBB. Consider that...

·         A5 Laboratories’ natural interferon (ng-INF), for which they have 3 patents pending and world-wide manufacturing rights...

·         Will increase the effectiveness of already established blockbuster drugs as much as 100 to 1,000-fold, thereby allowing for far lower dosages, far less toxicity, and far better results!

Click Here for new AFLB Report from Untapped Wealth

About A5 Laboratories, Inc.

A5 Labs is a contract research based organization servicing the pharmaceutical and biotechnology companies in North America. The company utilizes its research capabilities to license and acquire novel biotechnology products for development and commercialization.

Compensation and Other Disclosures

All material listed within was based upon information supplied by the company or from other sources believed to be reliable. This information contains forward-looking statements that involve risks and uncertainties. A company’s actual results could differ materially from those described within. We recommend you use the information provided as an initial starting point for conducting your own research on these companies in order to determine your own personal opinion before investing. We disclaim any and all liability as to the completeness or accuracy of the information and for any omissions of material facts.  Evergreen Marketing, Inc., parent company of The Green Baron Report, has received U.S. $4,500 for its coverage of A5 Laboratories, Inc. (BB: AFLB).

DEFINITION: Green Baron “Trading Alert”

"Trading Alert" – A stock introduced to our members supported by research provided by a respected third party.  These are companies that we believe are worthy of investment, and we expect a big move up particularly in the extreme short-term.  These stocks have not been thoroughly researched by Green Baron staff, and therefore are not supported by a more in-depth profile.  Under the sub-section “Trading Alerts” on our website and our reports, we will provide a link to the independent research or BUY recommendation, a short description of the Company, and in some cases, we will conduct a Green Baron audio-taped webcast interview to allow a key person discuss the merits of the Company.